Finance

Lists
GLUE:NASDAQ
Monte Rosa Therapeutics Inc
9,39 $
+0,86%
(+0,080) 1D
13 қар., 13:39:12 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GLUE...
Open
9,24 $
High
9,48 $
Low
8,95 $
Mkt. cap
802,38 млн
Avg. vol.
1,52 млн
Volume
599,29 м.
52-wk high
25,77 $
52-wk low
8,95 $
EPS
-1,38 $
Beta
1,41
Shares outstanding
85,45 млн
No. of employees
185
Open
9,24 $
High
9,48 $
Low
8,95 $
Mkt. cap
802,38 млн
Avg. vol.
1,52 млн
Volume
599,29 м.
52-wk high
25,77 $
52-wk low
8,95 $
EPS
-1,38 $
Beta
1,41
Shares outstanding
85,45 млн
No. of employees
185
News stories
From web sources and news partners
About Monte Rosa Therapeutics Inc
CEO-
Employees185
Founded2019
HeadquartersБостон, Массачусетс, Америка Құрама Штаттары
SectorHealth Care
Industry-
Analyst ratings
Based on 8 analysts giving stock ratings to GLUE in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for GLUE in the last 3 months.
Highest
Current 9,39 $
37,00 $ (+294,04%)
Average
25,14 $ (+167,73%)
Lowest
15,00 $ (+59,74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
37,00 $
+294%
11/10/2026
Robert Driscoll
Wedbush
Buy
Reiterated
27,00 $
+187,5%
11/06/2026
Unknown Analyst
Wedbush
Buy
Reiterated
27,00 $
+187,5%
11/06/2026
Derek Archila
Wells Fargo
Buy
Reiterated
25,00 $
+166,2%
11/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
28,00 $
+198,2%
11/05/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
25,00 $
+166,2%
11/06/2026
Faisal Khurshid
Jefferies
Buy
Maintained
15,00 $
+59,7%
11/05/2026
Unknown Analyst
UBS
Buy
Reiterated
19,00 $
+102,3%
10/12/2026
Alice Nettleton
UBS
Buy
Initiated
19,00 $
+102,3%
10/12/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
-
-
10/02/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
27,00 $
+187,5%
08/10/2026
Marc Frahm
TD Cowen
Buy
Reiterated
-
-
05/07/2026
Last report
2026 ж. 05 қар.
Fiscal period
Q3 2026
0,03 $ / -0,20 $
+114,90%beat
Revenue / Est. (USD)
54,37 млн / 33,89 млн
+60,42%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
2026 ж. қыр.
Revenue
2,78 млн
4,21 млн
8,97 млн
54,37 млн
Cost of goods sold
39,89 млн
41,82 млн
45,99 млн
3,28 млн
Cost of revenue
39,89 млн
41,82 млн
45,99 млн
3,28 млн
Research and development expenses
-
-
-
39,99 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,60 млн
12,42 млн
12,11 млн
13,03 млн
Operating expense
12,60 млн
12,42 млн
12,11 млн
53,02 млн
Total operating expenses
52,50 млн
54,24 млн
58,10 млн
56,30 млн
Operating income
-49,72 млн
-50,03 млн
-49,13 млн
-1,94 млн
Other non operating income
-
-
-
-
EBT including unusual items
-46,08 млн
-44,45 млн
-43,19 млн
3,78 млн
EBT excluding unusual items
-46,08 млн
-44,45 млн
-43,19 млн
3,78 млн
Income tax expense
59,00 мың
52,00 мың
208,00 м.
716,00 м.
Effective tax rate
-0,13%
-0,12%
-0,48%
18,95%
Other operating expenses
-
-
-
-
Net income
-46,14 млн
-44,50 млн
-43,40 млн
3,06 млн
Net profit margin
-1 658,94%
-1 057,08%
-483,91%
5,63%
Earnings per share
-0,55
-0,45
-0,43
0,03
Interest and investment income
3,69 млн
5,59 млн
5,92 млн
5,62 млн
Interest expense
-
-
-
-
Net interest expenses
3,69 млн
5,59 млн
5,92 млн
5,62 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,63 млн
-48,00 млн
-47,22 млн
205,00 м.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google қолданбалары